Clinical trials: Sexually Transmitted Disease (STD)
HIV Infection, Young Adult
Cohort of Young Adults Infected With HIV Since Birth or During Childhood
Background: With the improvement of the prognosis for HIV-infected infants, thanks to the availability of antiretroviral therapies, young adults infected with HIV since birth are becoming an emerging group among the HIV-infected…
- Trial name
- CO19 COVERTE (NCT01269632)
- Testing
- blood sampling, specific biological exams and biobank and self administered questionnaires
- Where
- France
- Volunteers
- 469 people, healthy volunteers welcome
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Human Papilloma Virus Infection
Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System
The objective is to establish that APTIMA HPV Assay performance on the PANTHER System is comparable to performance on the TIGRIS System.
- Trial name
- NCT01446198
- Where
- 3 sites in United States
- Volunteers
- 11,816 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
HIV Infections, Drug Abuse
Disulfiram Interactions With HIV Medications: Clinical Implications
The purpose of this study is to determine whether disulfiram might be a safe and effective treatment for cocaine and/or alcohol dependence in patients with HIV disease.
- Trial name
- NCT00878306
- Testing
- Disulfiram, Disulfiram + Efavirenz, Disulfiram + Atazanavir
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV Infection
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
The study will examine how safe and effective apricitabine is when given long term (as ongoing treatment) to HIV patients who have already completed the AVX-201 trial
- Trial name
- NCT00367952
- Testing
- apricitabine
- Where
- Australia
- Volunteers
- 42 people
- Sponsor
- Avexa
HIV Infections
A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
To compare effects on CD4 counts and serum viral RNA among HIV-seropositive, zidovudine (AZT)-experienced patients in three treatment arms: indinavir sulfate ( MK-639; Crixivan ) plus AZT plus lamivudine ( 3TC ) versus MK-639…
- Trial name
- NCT00002155
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)
To assess the safety and tolerance of multiple oral doses of nevirapine in combination with zidovudine (AZT); to get information on the pharmacokinetics (blood levels) and dose proportionality of nevirapine/AZT with multiple…
- Trial name
- NCT00000649
- Testing
- Nevirapine, Zidovudine
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Leukoplakia, Hairy, HIV Infections
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL).
- Trial name
- NCT00002026
- Testing
- Acyclovir
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV - Human Immunodeficiency Virus, HIV Antiretroviral Therapy (ART) Adherence
Improving the HIV Care Continuum With mHealth Technology
Youth living with HIV (YLHIV) face barriers to engagement and retention in HIV care, show poor medication adherence, and often fail to achieve and maintain viral suppression.
- Conditions
- HIV - Human Immunodeficiency Virus, HIV Antiretroviral Therapy (ART) Adherence, mHealth Application, mHealth Intervention
- Trial name
- NCT07631104
- Testing
- MindBodyU Intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of South Carolina
Human Immunodeficiency Virus (HIV), Tuberculosis (TB)
Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
The purpose of this study is to determine of once identified to the subjects infected with human immunodeficiency virus (positive VIH), to diagnose latent Tuberculosis, and to treat her with isoniazid for six months, measuring…
- Conditions
- Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Latent Tuberculosis Infection (LTI)
- Trial name
- HIV/TB (NCT01875952)
- Testing
- Isoniazid
- Where
- 2 sites in Mexico
- Volunteers
- 100 people
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
HIV Infections
C2P - Phase III: MPowerment and Community Promise
One of the objectives of the C2P coalition is the successful delivery of a CDC-endorsed community-level HIV prevention program aimed at changing the risk profiles of youth.
- Trial name
- NCT00381784
- Testing
- Printed materials, Peer advocates
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults
The purpose of this study is to determine the safety of and immune response to a DNA HIV vaccine, pGA2/JS7, followed by a modified vaccinia (smallpox) HIV vaccine, MVA/HIV62, in HIV uninfected adults.
- Trial name
- NCT00301184
- Testing
- pGA2/JS7 DNA, Modified vaccinia Ankara/HIV62
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019
Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) is a fixed dose combination regimen containing two nucleoside reverse transcriptase inhibitors and dolutegravir.
- Trial name
- NCT03016533
- Testing
- Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets
- Where
- 17 sites in United States, Botswana and 5 more
- Volunteers
- 100 people
- Sponsor
- ViiV Healthcare
HIV Infections
Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand
This study will evaluate the effectiveness of a combination of clinic- and community-based voluntary counseling and testing programs in preventing HIV in African and Thai communities.
- Trial name
- NCT00203749
- Testing
- Community-Based HIV VCT, Standard clinic-based VCT
- Where
- 5 sites in South Africa, Tanzania and 2 more
- Volunteers
- 192,814 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Common Wart, Warts Hand
Cantharidin and Occlusion in Verruca Epithelium
This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common…
- Conditions
- Common Wart, Warts Hand, Warts, Papillomavirus Infections
- Trial name
- COVE-1 (NCT03487549)
- Testing
- VP-102 Cantharidin topical film forming solution, VP-102 Cantharidin, topical film forming solution
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Papilloma Viral Infection
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
Primary objective To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men
- Trial name
- NCT02114385
- Testing
- V503, GARDASIL
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Protease Inhibitor
Atazanavir Twice Daily
The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir administered twice-daily relative to historical data from atazanavir/ritonavir 300/100 mg, given once daily.
- Trial name
- NCT00357721
- Testing
- Atazanavir Sulphate
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Human Immunodeficiency Virus, Depression
Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa
The purpose of this study is to test the efficacy of Our Family Our Future, an integrated intervention for preventing HIV and depression onset among adolescents.
- Conditions
- Human Immunodeficiency Virus, Depression, Sexually Transmitted Diseases
- Trial name
- NCT03231358
- Testing
- Our Family Our Future
- Where
- South Africa
- Volunteers
- 1,758 people, healthy volunteers welcome
- Sponsor
- Brown University
HIV Infection, Chronic Hepatitis B
Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France
Populations from Sub-Saharan Africa represent one of the most dynamic immigration flows in France and are among the most exposed to HIV infection and hepatitis B.
- Trial name
- PARCOURS (NCT02566148)
- Volunteers
- 2,468 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Human Immunodeficiency Virus, Obesity
Adipose Tissue and Immune Activation in HIV
The prevalence of HIV-associated wasting declined dramatically with the introduction of effective antiretroviral therapy (ART), but as patients survive longer on treatment the proportion of overweight (body mass index [BMI] >25…
- Trial name
- AIAC (NCT04439448)
- Testing
- dual-energy X-ray absorptiometry (DEXA) scan, Carotid and branchial artery ultrasound, 2-hour oral glucose tolerace test
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
HIV Infections, ART
Accelerated ART Initiation for PWHIV Who Are Out of Care
The main purpose of the study is to evaluate the effectiveness, of the ACCELERATE model of care to achieve HIV viral suppression at Week 24.
- Conditions
- HIV Infections, ART, Noncompliance, Patient
- Trial name
- ACCELERATE (NCT06374758)
- Testing
- The Accelerate model of care, bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Missouri-Columbia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.